FDA Greenlights First Gene Therapy Trial for Extremely Rare Pediatric Neurodegenerative Disorder
FDA Greenlights First Gene Therapy Trial for MLIV
In a groundbreaking development, the FDA has authorized a clinical trial for an experimental gene therapy aimed at treating Mucolipidosis Type IV (MLIV), an ultra-rare genetic neurological disorder that affects fewer than 100 children worldwide. This significant milestone was announced by the Mucolipidosis Type IV Foundation, which has been instrumental in the research and development of this therapy.
The Personal Journey Behind the Foundation
For Randy Gold, the president of the ML4 Foundation, and his wife Caroline, this achievement is not just professional; it is deeply personal. Their daughter, Eden, was diagnosed with MLIV at the tender age of 18 months, a diagnosis that sparked their commitment to fight for a treatment. “When Eden was diagnosed, there was no treatment available, and only early-stage research was offering families hopes of a different future,
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.